Head and Neck Pathology

, Volume 11, Issue 3, pp 338–345 | Cite as

Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma

  • Jonathan Chatzkel
  • James S. LewisJr.
  • Jessica C. Ley
  • Tanya M. Wildes
  • Wade Thorstad
  • Hiram Gay
  • Mackenzie Daly
  • Ryan Jackson
  • Jason Rich
  • Randal Paniello
  • Brian Nussenbaum
  • Jingxia Liu
  • Barry A. Siegel
  • Farrokh Dehdashti
  • Douglas Adkins
Original Paper
First Online:
Received:
Accepted:

Abstract

Determine if highly proliferative head and neck squamous cell carcinomas, assessed by pretreatment Ki-67 expression, respond more robustly to induction chemotherapy (IC) that is selectively toxic to cycling cells. Retrospective analysis of 59 patients treated with IC and chemoradiation. IC included either nab-paclitaxel, cisplatin, 5-FU and cetuximab (APF-C, n = 27) or docetaxel, cisplatin, 5-FU +/− cetuximab (TPF+/−C, n = 32). Ki-67 expression was assessed by immunohistochemistry. Tumor response (complete/partial/stable/progressive) at the primary site after two IC cycles was evaluated by visual examination in all patients. In the APF-C sub-group, tumor response (primary site and neck nodes) after two IC cycles was evaluated by computed tomography (CT) and fluorodeoxyglucose-positron emission tomography (FDG-PET)/CT. Ki-67 expression (median 66%, range: 16–97) did not differ across the tumor response categories assessed by visual examination (p = 0.95), CT (p = 0.30), or FDG-PET/CT (p = 0.65). Median decrease in summed SUVmax of measured lesions was 71.6% (range: 8.3–100%). The Pearson correlation coefficient between Ki-67 expression and the percent decrease in summed SUVmax was 0.48 (p = 0.02). Ki-67 expression was not different between those with or without a relapse (median: 60 and 71%, p = 0.10). In multivariate regression analysis (MVA) controlling for p16 positive oropharyngeal SCC status and smoking status, Ki-67 expression was not significantly associated with tumor response by visual examination (coefficient estimate −0.002, standard error 0.010, p = 0.84), CT (coefficient estimate −0.007, standard error 0.011, p = 0.54), FDG-PET/CT (coefficient estimate 0.006, standard error 0.008, p = 0.51), the percent decrease in summed SUVmax (coefficient estimate 0.389, standard error 0.222, p = 0.09), or relapse events (OR = 1.02(95%CI:0.99–1.05), p = 0.28). No significant relationships were found in MVA between pretreatment Ki-67 expression and tumor response to IC or to relapse.

Keywords

Ki-67 expression Chemotherapy sensitivity HNSCC 
This is a preview of subscription content, log in to check access.

Notes

Funding

We thank the Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis, Missouri for the use of the Clinical Trials Core, which provided protocol development and clinical trial support and for use of the Imaging and Response Assessment Core. The Siteman Cancer Center is supported in part by NCI Cancer Center Support Grant #P30 CA91842, (Eberlein, PI).

Compliance with Ethical Standards

Conflict of interest

Dr. Adkins has received Research Funding from Celgene. All other authors have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study, as part of a registry protocol.

References

  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. 2002. CA Cancer J Clin. 2005;55:74.CrossRefPubMedGoogle Scholar
  2. 2.
    Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med. 2001;345:1890–900.CrossRefPubMedGoogle Scholar
  3. 3.
    Hennessey PT, Westra WH, Califano JA. Human papillomavirus and head and neck squamous cell carcinoma: recent evidence and clinical implications. J Dent Res. 2009;88:300–6.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Adkins D, Ley J, Trinkaus K, Thorstad W, Lewis J Jr, Wildes T, et al. A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck. Cancer. 2013;119:766–73.CrossRefPubMedGoogle Scholar
  5. 5.
    Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998;58:2825–31.PubMedGoogle Scholar
  6. 6.
    Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996;14:737–44.CrossRefPubMedGoogle Scholar
  7. 7.
    Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16:273–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320:479–84.CrossRefPubMedGoogle Scholar
  10. 10.
    Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–500.CrossRefPubMedGoogle Scholar
  11. 11.
    Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626–34.CrossRefPubMedGoogle Scholar
  12. 12.
    Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005;6:279–86.CrossRefPubMedGoogle Scholar
  13. 13.
    Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–78.CrossRefPubMedGoogle Scholar
  14. 14.
    Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–27.CrossRefPubMedGoogle Scholar
  15. 15.
    Licitra L, Mesia R, Rivera F, Remenar E, Hitt R, Erfan J, et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol. 2011;22:1078–87.CrossRefPubMedGoogle Scholar
  16. 16.
    Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.CrossRefPubMedGoogle Scholar
  17. 17.
    Silva SD, Agostini M, Nishimoto IN, Coletta RD, Alves FA, Lopes MA, et al. Expression of fatty acid synthase, ErbB2 and Ki-67 in head and neck squamous cell carcinoma. A clinicopathological study. Oral Oncol. 2004;40:688–96.CrossRefPubMedGoogle Scholar
  18. 18.
    Pich A, Chiusa L, Navone R. Prognostic relevance of cell proliferation in head and neck tumors. Ann Oncol. 2004;15:1319–29.CrossRefPubMedGoogle Scholar
  19. 19.
    Lavertu P, Adelstein DJ, Myles J, Secic M. P53 and Ki-67 as outcome predictors for advanced squamous cell cancers of the head and neck treated with chemoradiotherapy. Laryngoscope. 2001;111:1878–92.CrossRefPubMedGoogle Scholar
  20. 20.
    Kropveld A, Slootweg PJ, Blankenstein MA, Terhaard CH, Hordijk GJ. Ki-67 and p53 in T2 laryngeal cancer. Laryngoscope. 1998;108:1548–52.CrossRefPubMedGoogle Scholar
  21. 21.
    Couture C, Raybaud-Diogene H, Tetu B, Bairati I, Murry D, Allard J, et al. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer. 2002;94:713–22.CrossRefPubMedGoogle Scholar
  22. 22.
    Homma A, Furuta Y, Oridate N, Nakano Y, Kohashi G, Yagi K, et al. Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Clin Cancer Res. 1999;5:801–6.PubMedGoogle Scholar
  23. 23.
    Petit T, Wilt M, Velten M, Millon R, Rodier JF, Borel C, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer. 2004;40:205–11.CrossRefPubMedGoogle Scholar
  24. 24.
    Ellis MJ, Tao Y, Luo J, A’Hern R, Evans DB, Bhatnagar AS, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 2008;100:1380–8.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Oncotypedx. Cited 1/14/2016. http://www.oncotypedx.com/.
  26. 26.
    Prosigna. Cited 1/14/2016. http://prosigna.com.
  27. 27.
    Perez EA. Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther. 2009;8:2086–95.CrossRefPubMedGoogle Scholar
  28. 28.
    Yewale C, Baradia D, Vhora I, Patil S, Misra A. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials. 2013;34:8690–707.CrossRefPubMedGoogle Scholar
  29. 29.
    Schell A, Ley J, Wu N, Trinkaus K, Wildes TM, Michel L, et al. Nab-paclitaxel-based compared to docetaxel-based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck. Cancer Med. 2015;4:481–9.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Ensley JF, Jacobs JR, Weaver A, Kinzie J, Crissman J, Kish JA, et al. Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer. 1984;54:811–4.CrossRefPubMedGoogle Scholar
  31. 31.
    Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.CrossRefGoogle Scholar
  33. 33.
    Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma A, et al. Measurement of clinical and subclinical tumour response using [18 F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J cancer. 1999;35:1773–82.CrossRefPubMedGoogle Scholar
  34. 34.
    Scantlebury JB, Luo J, Thorstad WL, El-Mofty SK, Lewis JS Jr. Cyclin D1-a prognostic marker in oropharyngeal squamous cell carcinoma that is tightly associated with high-risk human papillomavirus status. Hum Pathol. 2013;44:1672–80.CrossRefPubMedGoogle Scholar
  35. 35.
    Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A’Hern R, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99:167–70.CrossRefPubMedGoogle Scholar
  36. 36.
    Goetz MP, Suman VJ. Window-of-opportunity trials in the preoperative setting: insights into drug development for estrogen receptor–positive breast cancer. J Clin Oncol. 2016;34:1970–2.CrossRefPubMedGoogle Scholar
  37. 37.
    Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014;32(25):2735–43.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Haddad R, O’Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013;14(3):257–64.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Jonathan Chatzkel
    • 1
  • James S. LewisJr.
    • 3
  • Jessica C. Ley
    • 1
  • Tanya M. Wildes
    • 1
    • 2
  • Wade Thorstad
    • 2
    • 4
  • Hiram Gay
    • 2
    • 4
  • Mackenzie Daly
    • 2
    • 4
  • Ryan Jackson
    • 2
    • 5
  • Jason Rich
    • 2
    • 5
  • Randal Paniello
    • 2
    • 5
  • Brian Nussenbaum
    • 2
    • 5
  • Jingxia Liu
    • 6
  • Barry A. Siegel
    • 2
    • 7
  • Farrokh Dehdashti
    • 2
    • 7
  • Douglas Adkins
    • 1
    • 2
  1. 1.Department of Internal Medicine, Division of Medical OncologyWashington University School of MedicineSt. LouisUSA
  2. 2.Alvin J. Siteman Cancer CenterWashington University School of MedicineSt. LouisUSA
  3. 3.Department of PathologyMicrobiology, and Immunology Vanderbilt University School of MedicineNashvilleUSA
  4. 4.Department of Radiation OncologyWashington University School of MedicineSt. LouisUSA
  5. 5.Department of Otolaryngology, Division of Head and Neck SurgeryWashington University School of MedicineSt. LouisUSA
  6. 6.Division of Public Health SciencesWashington University School of MedicineSt. LouisUSA
  7. 7.Mallinckrodt Institute of Radiology, Division of Nuclear MedicineWashington University School of MedicineSt. LouisUSA

Personalised recommendations